Yahoo Web Search

Search results

1. www.ncbi.nlm.nih.gov › books › NBK535374Bullous Pemphigoid - StatPearls - NCBI Bookshelf

   www.ncbi.nlm.nih.gov › books › NBK535374

   Mar 2, 2023 · Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disorder, representing 80% of subepidermal immunobullous cases. Bullous pemphigoid most commonly affects elderly patients between the ages of 60 to 80 years.

   • Author: Dana Baigrie, Vinod Nookala

   • Published: 2023/03/02

2. www.ncbi.nlm.nih.gov › pmc › articlesA blistering new era for bullous pemphigoid: A scoping review ...

   www.ncbi.nlm.nih.gov › pmc › articles

   Sep 4, 2021 · Bullous pemphigoid (BP) is a severe autoimmune blistering skin disorder that primarily causes disease in the older population and is the most prevalent subepidermal variant of the pemphigoid diseases.

   • Author: Subaina Naeem Khalid, Zeest Ali Khan, Muhammad Hamza Ali, Talal Almas, Tarek Khedro, Vikneswaran Raj...

   • Publish Year: 2021

3. www.researchgate.net › publication › 325059837(PDF) Bullous Pemphigoid - ResearchGate

   www.researchgate.net › publication › 325059837

   May 9, 2018 · Bullous pemphigoid (BP) is an autoimmune bullous disease caused by autoantibodies against BP180 in the epidermal basement membrane. Autoantibody-mediated complement activation is an important...

4. www.ncbi.nlm.nih.gov › pmc › articlesInterventions for bullous pemphigoid: An updated systematic ...

   www.ncbi.nlm.nih.gov › pmc › articles

   Sep 1, 2021 · Background: Bullous pemphigoid (BP) is a widely recognized autoimmune blistering disease (AIBD) linked with a high incidence of morbidity and mortality. The aim of this study was to evaluate the available findings of randomized clinical trial studies to update interventions for Bullous pemphigoid.

   • DOI: 10.47176/mjiri.35.111
   • Published: 2021

   • Publication: Med J Islam Repub Iran. 2021; 35: 111.

5. journals.sagepub.com › doi › fullSerum Biomarkers in Bullous Pemphigoid: A Systematic Review

   journals.sagepub.com › doi › full

   Jul 29, 2024 · Bullous pemphigoid (BP) is the most common type of subepidermal blistering disease, usually observed in the elderly population, with a mean age of presentation between 66 and 83 years. BP is a psychosocially ladened disease, with many patients experiencing negative body image, social isolation, and depression.

6. link.springer.com › article › 10Advancements in Bullous Pemphigoid Treatment: A ... - Springer

   link.springer.com › article › 10

   • Cached

   Dec 29, 2023 · Bullous pemphigoid (BP) is a common autoimmune bullous disease affecting mainly the elderly, with rising incidence due to increased life expectancy. This disease is characterized by tense bullous lesions on normal or erythematous skin, accompanied by pruritus.

7. People also ask

   What is bullous pemphigoid?

   • Bullous pemphigoid most commonly affects elderly patients between the ages of 60 to 80 years. While the clinical presentation of bullous pemphigoid is broad, the immunobullous skin disorder characteristically presents with tense bullae and intense generalized pruritus.

   Bullous Pemphigoid - StatPearls - NCBI Bookshelf

   www.ncbi.nlm.nih.gov/books/NBK535374/

   See all results for this question

   How is bullous pemphigoid treated?

   • The mainstay of treatment for bullous pemphigoid is systemic corticosteroids, but treatment ultimately depends on comorbidities and the extent of the disease. For localized disease, less than 20% body surface area in an elderly patient, super-potent topical steroids such as clobetasol may be used.

   Bullous Pemphigoid - StatPearls - NCBI Bookshelf

   www.ncbi.nlm.nih.gov/books/NBK535374/

   See all results for this question

   What are the diagnostic criteria for bullous pemphigoid?

   • Their reports stated three out of four diagnostic criteria have a sensitivity of 90% and specificity of 83%. The mainstay of treatment for bullous pemphigoid is systemic corticosteroids, but treatment ultimately depends on comorbidities and the extent of the disease.

   Bullous Pemphigoid - StatPearls - NCBI Bookshelf

   www.ncbi.nlm.nih.gov/books/NBK535374/

   See all results for this question

   What is a remission strategy for bullous pemphigoid?

   • This strategy aims to attain rapid remission, minimizing instances of relapse and reducing the extent of immunosuppression. This undertaking is of great importance in order to help patients find a relief from this very disabling ailment. van Beek N, et al. IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases.

   Advancements in Bullous Pemphigoid Treatment: A ... - Springer

   link.springer.com/article/10.1007/s40257-023-00832-1

   See all results for this question

8. www.jidonline.org › article › S0022-202X(19)33399-8Recent Advances in Understanding Pemphigus and Bullous Pemphigoid

   www.jidonline.org › article › S0022-202X(19)33399-8

   Bullous pemphigoid (BP) is an autoantibody-mediated disease that usually occurs in the elderly but may be seen at all ages (Culton et al., 2019). It is characterized by tense large blisters on skin and in a minority of cases, oral erosions. Blisters may be on normal-appearing or inflamed skin.